Mpox Clade 1b Detected: How Rapid Testing with Vivalytic Can Aid in Containment
Mpox Clade 1b Detected: How Rapid Testing with Vivalytic Can Aid in Containment
Mpox Clade 1b Detected: How Rapid Testing with Vivalytic Can Aid in Containment
Mpox, formerly known as Monkeypox, is a viral infection that has seen significant global attention due to recent outbreaks. As of August 2024, the UK has reported a total of 4,018 confirmed and highly probable mpox cases since May 2022 (1).
In October, the UK Health Security Agency (UKHSA) reported its first case of Clade 1b Mpox (2)—a more severe strain that has been spreading in the Democratic Republic of Congo (DRC) and other parts of Africa, prompting the World Health Organisation to declare it a public health emergency of international concern in August 2024 (3). This detection has led UKHSA to initiate contact tracing and monitor for potential further spread. Although the public risk is currently low, quick identification and containment remain vital for managing any risks associated with this High Consequence Infectious Disease (HCID).
According to a report on Mpox diagnostic testing published by the UKHSA, PCR testing remains the gold standard for Mpox detection, offering unmatched sensitivity and specificity essential for accurate diagnosis and effective containment (4). At Randox, with a strong commitment to public health and diagnostic innovation, we offer the Vivalytic MPXV Rapid Test to support healthcare professionals in identifying cases quickly and accurately, helping to strengthen containment efforts.
Understanding Mpox Clade 1b and Its Implications
Clade 1b of the mpox virus is part of the High Consequence Infectious Disease (HCID) category due to its higher transmission potential and more severe symptom profile compared to other strains. With a broad incubation period ranging from 5 days to 3 weeks (5), symptoms include:
• Skin rashes that progress to blisters or ulcers
• Fever, headaches, and muscle aches
• Swollen lymph nodes
• In severe cases, respiratory issues or widespread skin lesions
o Mpox infection is often self-limiting and usually lasts 2 to 4 weeks (5).
The transmission of mpox occurs through close contact with infectious lesions, bodily fluids, or contaminated materials. This can include skin-to-skin contact during sexual or intimate contact, as well as sharing items like bedding, towels, or clothing. Mpox infection is often self-limiting and usually lasts 2 to 4 weeks (5) and has a mortality rate estimated to be between 1% and 11% (6). Clade 1b’s recent spread outside of endemic regions, including cases in Germany, Sweden, and India (7) signals the need for proactive diagnostic and containment strategies.
Enter Vivalytic
The Vivalytic MPXV Rapid Test provides healthcare professionals with a comprehensive tool for detecting both Clade I (HCID, including Clade 1b) and Clade II of the Mpox Virus, as well as other Orthopoxvirus species. Its rapid and reliable performance is particularly valuable in high-stakes scenarios, where early detection can help prevent further spread. Key features include.
Features of the Vivalytic MPXV Panel
- Quick Results: Results in just 45 minutes allow for timely decision-making.
- Comprehensive Detection: This test identifies both Clade I (HCID, including Clade 1b) and Clade II of the Mpox Virus, as well as other Orthopoxvirus species such as cowpox and vaccinia virus.
- Minimal Sample Requirement: Only 300 µL needed, reducing sample handling and maintaining accuracy.
- Intuitive Workflow: The compact Vivalytic streamlines the entire molecular workflow through a 4-step process—scanning, inputting, adding the sample to the cartridge, and receiving results on the touchscreen display, all at the point of care.
| Detectable Pathogens | |
|---|---|
| Monkeypox Virus (Clade I, Clade II) | Non-variola Orthopoxvirus species (Coqpox Virus, Ectromelia Virus, Monkeypox Virus, Taterapox Virus, Vaccinia Virus) |
Supporting Public Health Responses with Randox
As part of our commitment to public health, Randox provides high-quality diagnostic tools designed to address infectious diseases like mpox. The Vivalytic MPXV Rapid Test supports rapid detection and strengthens the healthcare system’s ability to respond to emerging infectious threats. With the first UK case of Clade 1b now identified, rapid testing and response are essential components in the continued effort to protect public health.
Learn more about the Vivalytic, with one of the largest test menus on the market and how it can support your testing needs this winter here: Vivalytic | Point of Care | Randox Laboratories
Contact marketing@randox.com for more information
References
- UK (2024). Mpox (Mpox) outbreak: epidemiological overview, 8 August 2024. [online] GOV.UK. Available at: https://www.gov.uk/government/publications/Mpox-outbreak-epidemiological-overview/mpox-Mpox-outbreak-epidemiological-overview-8-august-2024.
- Thomas, R. (2024). First case of new potentially deadly mpox strain Clade 1b detected in UK. [online] The Independent. Available at: https://www.independent.co.uk/news/health/mpox-uk-clade-1b-monkeypox-b2638777.html [Accessed 6 Nov. 2024].
- World health Organisation (WHO). (2024). Mpox outbreak. [online] Available at: https://www.who.int/emergencies/situations/mpox-outbreak.
- UK Health Security Agency (UKHSA) (2024). Mpox (monkeypox): diagnostic testing. [online] GOV.UK. Available at: https://www.gov.uk/guidance/monkeypox-diagnostic-testing#sampling-for-diagnostic-testing.
- Guarner, J., del Rio, C. and Malani, P.N. (2022). Monkeypox in 2022—What Clinicians Need to Know. JAMA, [online] 328(2). doi:https://doi.org/10.1001/jama.2022.10802.
- CDC (2024). Mpox. [online] Mpox. Available at: https://www.cdc.gov/mpox/?CDC_AAref_Val=https://www.cdc.gov/poxvirus/mpox/travel/index.html [Accessed 6 Nov. 2024].
- Reed, J. (2024). New mpox strain spreads to household contacts in the UK. BBC News. [online] 4 Nov. Available at: https://www.bbc.co.uk/news/articles/cx27q0y6rl9o.
Fight Flu Season with Vivalytic
Fight Flu Season with Vivalytic!
As we enter the Winter 2024/25 flu season, healthcare providers and patients face the co-circulation of influenza, RSV, and SARS-CoV-2. This combination of respiratory pathogens presents unique challenges, particularly for vulnerable groups, and highlights the critical need for rapid, accurate diagnostics. Vaccination among frontline healthcare workers remains essential to reduce transmission, protect high-risk patients, and prevent staff shortages in healthcare facilities.
The Seasonal Threat of Respiratory Infections
Every year, influenza outbreaks affect millions globally, especially during winter. In England, 2023/2024 saw 2,776 flu-related deaths, highlighting the burden on healthcare systems. Vulnerable groups, including older adults, pregnant women, and those with chronic conditions, face heightened risks of severe outcomes like pneumonia or ICU admissions.
Pamela Rendi-Wagner, Director of the European Centre for Disease Prevention and Control, stressed that “vaccination is one of the most effective measures to protect vulnerable populations from severe disease, hospitalisation, and death.” Recent data shows significant variability in flu vaccination rates among older adults, ranging from 12% to 78% across Europe, with only two countries exceeding 75% coverage.
Vaccination remains the cornerstone of flu prevention for high-risk groups like the elderly, immunocompromised, and healthcare workers. However, diagnostic testing plays an equally vital role this flu season. Rapid and accurate testing prevents unnecessary hospitalisations, reduces severe outcomes in vulnerable populations, and ensures effective use of healthcare resources.
Enter Vivalytic
Accurate and rapid diagnosis is essential for effective treatment and control of respiratory infections, especially during flu season. By identifying the specific pathogen, healthcare providers can tailor treatment plans, combat anti-microbial resistance, reduce the spread within communities, and alleviate pressure on healthcare systems.
Enter Vivalytic; and with it the SARS, Flu A/B, and RSV Panel, offering an all-in-one solution for simultaneous testing of key respiratory pathogens. This panel ensures that healthcare professionals can diagnose and differentiate between influenza, RSV, and SARS-CoV-2 swiftly, providing crucial information to guide patient management.
Features of the Vivalytic SARS, Flu A/B and RSV Panel
- All-in-One Solution: Multi-pathogen testing with a single cartridge, eliminating the need for complex manual preparation.
- Rapid Results: With a turnaround time of just 53 minutes, the Vivalytic Flu panel enables swift decision-making, crucial in time-sensitive cases from a single nasopharyngeal or oropharyngeal swab sample.
- User-Friendly Design: An intuitive touchscreen interface requires minimal training, making it ideal for use in a variety of healthcare settings, including those with non-specialist operators.
| Detectable Pathogens |
|---|
| SARS-CoV-2 (E gene & N gene) |
| Influenza A and Influenza B |
| Human Respiratory Syncytial Virus |
Meeting the Challenges of the 2024/2025 Flu Season
As flu season progresses, the need for efficient and reliable diagnostics becomes ever more apparent. Fight Flu Season with Vivalytic, the SARS, Flu A/B, and RSV Panel is not only a valuable tool for diagnosing individual cases but also plays a critical role in protecting public health by enabling rapid response and management of outbreaks.
Learn more about the Vivalytic, with one of the largest test menus on the market and how it can support your testing needs this winter here: Vivalytic | Point of Care | Randox Laboratories
Contact marketing@randox.com for more information
Combatting AMR with Rapid UTI Diagnostics
Antimicrobial Resistance Awareness Week: Combatting AMR with Rapid UTI Diagnostics
Antimicrobial Resistance (AMR) poses one of the most critical health challenges of our time. Indeed, the World Health Organisation (WHO) has identified AMR as one of the top 10 global health threats (1). Furthermore, in the UK, AMR is recognised on the National Risk Register (2), reflecting the severity of the issue at both national and international levels. With AMR-related deaths reaching 4.95 million globally in 2019 (1), including 1.27 million directly attributed to resistant infections (1), urgent and coordinated action is required to preserve the efficacy of existing antimicrobials.
As part of Antimicrobial Resistance Awareness Week (18–24 November), we are focusing on the critical role of rapid diagnostics in combating AMR. Specifically, we are introducing the Randox Vivalytic UTI Rapid Test as a valuable tool in this global effort. By enabling faster and more accurate detection of infections, this innovative diagnostic technology supports the targeted use of antibiotics, thereby helping to reduce unnecessary prescriptions and mitigate the spread of resistance.
Understanding AMR: The Need for Effective Screening and Targeted Treatment
AMR develops when microorganisms such as bacteria, viruses, fungi, and parasites evolve to resist the effects of antimicrobial medicines. While this resistance occurs naturally, it is significantly accelerated by factors such as the overuse and misuse of antibiotics, poor infection control, and the slow pace of new antimicrobial drug development. Consequently, the implications of AMR extend far beyond infection treatment: surgeries, cancer therapies, and routine medical procedures also rely heavily on effective antimicrobials to prevent infections. Therefore, this underscores the pressing need to manage resistance effectively and proactively.
For instance, routine treatments for UTIs heavily depend on antibiotics. UTIs are among the most common bacterial infections, particularly affecting women, with over 50% experiencing a UTI at least once in their lives (3). However, with resistance levels increasing, it becomes crucial to avoid unnecessary antibiotic prescriptions. Additionally, when antibiotics are prescribed, they must be carefully targeted to maximise efficacy and minimise resistance development. In this context, rapid diagnostics play a pivotal role by enabling precise and timely identification of infections, which ensures that treatments are both effective and appropriate.
Introducing the Vivalytic UTI Rapid Test
The Randox Vivalytic UTI Rapid Test offers a cutting-edge solution for the efficient screening and diagnosis of UTIs. Unlike traditional culture methods—which, according to a recent study, take an average of 2.75 days to yield results (4)—the Vivalytic UTI Rapid Test is a cartridge-based PCR test specifically designed for in-clinic use, delivering results in just 2.5 hours. This rapid turnaround is transformative in the management of UTIs, where timely diagnosis is crucial to preventing the progression of infections. Moreover, it helps to minimise unnecessary antibiotic use by ensuring treatment is both prompt and precisely targeted, ultimately supporting the fight against antimicrobial resistance.
Key Features of the Vivalytic UTI Rapid Test:
- Comprehensive Detection: The Vivalytic UTI Rapid Test identifies 16 uropathogens, encompassing both gram-negative and gram-positive bacterial species, in just 150 minutes—significantly faster than traditional culture methods.
- AMR Gene Identification: This advanced test also detects 7 antimicrobial resistance genes, including those conferring resistance to methicillin (mecA) and vancomycin (vanA and vanB), as well as genes associated with trimethoprim resistance (dfrA1, dfrA5, dfrA12, dfrA17). This capability supports targeted treatment decisions and helps in combating antimicrobial resistance.
- Wide Application: Designed for versatility, the test is suitable for various healthcare settings, from GP practices to hospitals. It facilitates UTI diagnosis across diverse use cases, including catheter-associated UTIs and pre-surgical screenings for patients with conditions such as benign prostatic hyperplasia (BPH) or renal stones.
Additionally, a recent study demonstrated that the Vivalytic UTI Rapid Test achieved diagnostic accuracy exceeding 90% for 16 bacterial species, providing a reliable and efficient solution for rapid pathogen identification in UTI cases (4).
The Role of Rapid Diagnostics in Combating AMR
Rapid diagnostic tests, such as the Vivalytic UTI Rapid Test, play a critical role in addressing antimicrobial resistance (AMR) and improving patient care through the following:
- Reducing Misuse of Antibiotics: By rapidly identifying the specific bacteria responsible for the infection and detecting resistance genes, clinicians can prescribe antibiotics only when necessary. This targeted approach ensures that the most effective treatment is selected, helping to combat antibiotic misuse.
- Supporting Antimicrobial Stewardship: Point-of-care testing directly supports the goals outlined in the UK’s AMR 5-Year National Action Plan, which aims to reduce antibiotic consumption by 5% and ensure that 70% of antibiotics are sourced from safer, first-line options (5). Rapid tests enable optimised antibiotic usage, contributing to these national targets and the broader fight against AMR.
- Enhancing Patient Outcomes: Faster and more accurate diagnostics at the point of care enable timely and targeted treatment, reducing the risk of complications such as severe UTI-related kidney infections. Furthermore, a study on the Vivalytic UTI Rapid Test demonstrated that pathogen detection rates were slightly higher when tests were conducted immediately on-site, underscoring the importance of rapid diagnostics in delivering better patient outcomes (4).
AMR and the Future of Healthcare
The rise in AMR jeopardises the future of modern medicine. An estimated 10 million lives could be lost per year by 2050 (6), according to a review commissioned by the UK Prime Minister. Without effective diagnostics and treatments, procedures such as hip replacements, caesarean sections, and cancer therapies could become significantly more dangerous. This is due to the heightened risk of untreatable infections (1). Addressing this escalating threat requires innovation, education, and unwavering commitment.
AMR also imposes immense economic consequences. The World Bank projects that by 2050, AMR could add an extra US$1 trillion to global healthcare costs. It may also cause annual GDP losses ranging from US$1 trillion to US$3.4 trillion as early as 2030 (7). These economic burdens highlight the urgent need for global action.
Addressing AMR is crucial to achieving the Sustainable Development Goals (SDGs) outlined by the United Nations (UN). Progress in areas such as access to clean water, sustainable food production, and responsible antimicrobial use is vital in mitigating AMR. However, rising levels of AMR exacerbate challenges related to health, poverty reduction, food security, and economic growth (8). Coordinated efforts across multiple sectors are essential to tackle this complex issue effectively.
Randox is proud to lead the charge in the fight against antimicrobial resistance (AMR), equipping healthcare professionals with innovative tools such as the Vivalytic UTI Rapid Test. By enabling timely and accurate diagnoses, we contribute to preserving the efficacy of antimicrobials and safeguarding their availability for future generations.
This Antimicrobial Resistance Awareness Week, join us in highlighting the critical importance of AMR management and the transformative role of rapid diagnostics in creating a safer, healthier future for all.
Learn more about the urgency of AMR on the WHO website: Antimicrobial resistance.
For further details about the Vivalytic UTI Rapid Test, visit Vivalytic | UTI Rapid Test | Randox Laboratories or reach out to us at marketing@randox.com.
References
- World Health Organization (2023). Antimicrobial resistance. [online] World Health Organization. Available at: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance.
- HM Government (2023). National Risk Register 2023 Edition. [online] Available at: https://assets.publishing.service.gov.uk/media/64ca1dfe19f5622669f3c1b1/2023_NATIONAL_RISK_REGISTER_NRR.pdf.
- Bono MJ, Reygaert WC. Urinary Tract Infection. Nih.gov. Published 2018. https://www.ncbi.nlm.nih.gov/books/NBK470195/
- Hartmann, J., Fritzenwanker, M., Imirzalioglu, C., Hain, T., Arneth, B.M., and Wagenlehner, F.M.E., 2024. Point-of-care Testing in Complicated Urinary Tract Infection: Evaluation of the Vivalytic One Urinary Tract Infection Analyser for Detecting Uropathogenic Bacteria and Antimicrobial Resistance in Urine Samples of Urological Patients in a Point-of-care Setting. European Urology Focus. Available at: https://doi.org/10.1016/j.euf.2024.09.018
- Department of Health and Social Care (2024). UK 5-year action plan for antimicrobial resistance 2024 to 2029. [online] GOV.UK. Available at: https://www.gov.uk/government/publications/uk-5-year-action-plan-for-antimicrobial-resistance-2024-to-2029.
- O’Neill, J. (2016). Tackling Drug-resistant Infections Globally: Final Report and Recommendations. Archives of Pharmacy Practice, 7(3), p.110. doi:https://doi.org/10.4103/2045-080x.186181.
- World Bank (2017). Drug-Resistant Infections: A Threat to Our Economic Future. [online] World Bank. Available at: https://www.worldbank.org/en/topic/health/publication/drug-resistant-infections-a-threat-to-our-economic-future.
- World Health Organization (WHO) (2021). Antimicrobial resistance and the United Nations sustainable development cooperation framework: guidance for United Nations country teams. [online] www.who.int. Available at: https://www.who.int/publications/i/item/9789240036024.
Acusera 24Ā·7 and Data Innovations – Automated QC Data Upload
Automated QC Data Upload to Acusera 24·7
Now Available via Instrument Manager™ from Data Innovations
Randox Laboratories in conjunction with Data Innovations are pleased to announce the launch of a new driver that enables seamless, automated QC data upload via API from any instrument connected to Instrument Manager (IM) directly into Acusera 24.7. This new feature eliminates the need for manual data entry, reduces transcription errors and improves laboratory efficiency.
What you need to know
Uni-Directional License – Anyone wishing to avail of automated QC data upload to Acusera 24.7 will need a uni-directional license for Instrument Manager. A new license can be requested directly from a Data Innovations representative, or an existing license previously used for an analyser may be re-purposed.
Driver Download – Once a license has been secured, you will be required to download the Acusera 24.7 Driver from the MY DI Community website – https://datainnovations.my.site.com/s/drivers. To locate the driver simply select Randox from the Manufacturer drop down menu and then select Acusera 24.7 from the list of available drivers.
Configuration – Once the driver has been downloaded, you will receive help files that document the process to be followed. The same steps are to be followed as with connecting any instrument or analyser to Instrument Manager.
Once the driver has been successfully set up, Instrument Manager will automatically send QC data to Acusera 24.7, removing the need for manual data entry.
Key Considerations
- You must have have an Acusera 24.7 license and configured your Acusera 24.7 account before connecting to Instrument manager.
This new capability allows laboratories to optimise workflows, reduce errors, and streamline QC data management.
About Data Innovations
Data Innovations is a global software company that is passionate about excellence in patient care. Through innovative solutions and world-class service, they enable enterprise management of hospitals and independent laboratories. Founded in 1989 with headquarters in Vermont, Data Innovations serves more than 6,000 hospitals and laboratories in 80+ countries.
What is Instrument Manager?
Laboratory Information Management Systems (LIMS) by Data Innovations LLC
Instrument Manager™ (IM) is a truly vendor-neutral middleware platform that allows for the connection of any clinical lab instrument to any Lab Information System (LIS), with a library of over 1,000 instrument drivers. IM offers a suite of lab enablement solutions spanning productivity, quality, analytics, performance and reliability.
Labs using IM auto verification with time-saving workflows are able to achieve quicker turnaround times and increased productivity. IM quality assurance programs ensure that all connected instruments deliver the most accurate possible test results.
Candida auris: An Urgent Fungal Threat
An Urgent Fungal Threat: Tackling Candida auris in Healthcare Environments
Candida auris (C. auris), is an emerging fungal threat that has garnered global attention due to its multidrug-resistant nature and ability to cause severe, life-threatening infections. First identified in 2009, C. auris has quickly spread worldwide, particularly in healthcare settings, posing a significant challenge to both clinicians and public health professionals.
Understanding Candida auris
Candida auris is a yeast-like fungus that can lead to severe infections, especially in patients with compromised immune systems or underlying health conditions. It is frequently found in healthcare environments such as hospitals and long-term care facilities. The most concerning aspect of C. auris is its ability to persist on surfaces, increasing the risk of outbreaks in these environments. Once introduced into a healthcare setting, it can rapidly spread from one patient to another, making infection control a significant challenge.
In Illinois alone, 921 C. auris cases were confirmed between 2016 and 2022 (1). Additionally, in 2022, 2377 cases of C. auris were reported to the CDC (2), further highlighting the increase in cases each year. In Europe, survey responses were received from all 30 invited EU/EEA countries. From 2013 to 2021, a total of 1,812 Candida auris cases were reported by 15 of these countries. The number of cases nearly doubled from 335 in 2020 to 655 in 2021, indicating a significant increase compared to previous years (3).
C. auris primarily causes bloodstream infections, but it can also infect wounds, the respiratory tract, and the ear. Patients in critical care, especially those using invasive medical devices such as ventilators, catheters, or feeding tubes, are particularly susceptible. In fact, data indicates that more than one in three people with an invasive C. auris infection affecting the blood, heart, or brain, do not survive (1).
The Growing Threat of Multidrug Resistance
One of the major concerns surrounding C. auris is its resistance to multiple classes of antifungal medications, which are typically used to treat Candida infections. This multidrug resistance often leads to treatment failure and poor outcomes in affected patients. In addition to its drug resistance, Candida auris is often misidentified as other Candida species using standard laboratory methods, further delaying appropriate treatment.
The Importance of Rapid and Accurate Detection
Given the risks posed by Candida auris, rapid detection is crucial for preventing the spread of this dangerous fungus. Early identification allows healthcare professionals to implement strict infection control measures such as isolating patients, cleaning and disinfecting affected areas, and preventing further transmission within healthcare facilities. However, traditional detection methods may be slow and prone to misidentification, making timely response difficult.
Enter Vivalytic
The early identification and containment of Candida auris are essential to prevent large-scale outbreaks. This is especially important in healthcare environments where patients may be vulnerable. The Vivalytic’s rapid detection of C. auris colonisation and infection allows for earlier implementation of infection control measures. This reduces the burden on public health systems and helps save lives.
At Randox Laboratories, the focus is on advancing the detection of infectious diseases like Candida auris. The Vivalytic, developed with Bosch, offers a reliable and accurate testing solution. This supports healthcare providers in protecting patients and controlling the spread of the fungus. Real-time PCR technology is used by the Vivalytic Candida auris test to detect DNA from swabs. These swabs may be taken from the axilla, groin, nasal, or rectal regions.
Key Benefits of Vivalytic Testing for Candida auris:
- Quick Results: The Vivalytic provides results in under 1 hour, enabling healthcare providers to make swift, informed decisions about patient care and infection control. This quick turnaround is essential for both treating the patient and containing the spread of Candida auris within a healthcare facility.
- Simple, 4-Step Process: The test uses a convenient 4-step process, from scanning the sample to receiving the results, making it easy to use in both laboratory and non-laboratory settings. The system’s fully automated, cartridge-based platform minimises the risk of contamination and simplifies workflow.
- Accurate Detection: The real-time PCR method used by Vivalytic ensures precise detection of Candida auris, even in cases where traditional methods might misidentify the fungus. This accuracy is vital in initiating appropriate antifungal treatment and curbing the infection.
- Convenient for Various Settings: The Vivalytic platform is designed to be used in a wide range of settings, from large laboratories to point-of-care environments, making it versatile and adaptable to the needs of different healthcare providers.
| Detectable Pathogens |
|---|
| Candida auris |
References
- dph.illinois.gov. (n.d.). Candida auris (C. auris). [online] Available at: https://dph.illinois.gov/topics-services/diseases-and-conditions/infectious-diseases/candida-auris.html.
- CDC (2024). Tracking C. auris. [online] Candida auris (C. auris). Available at: https://www.cdc.gov/candida-auris/tracking-c-auris/index.html.
- Kohlenberg, A., Monnet, D.L. and Plachouras, D. (2022). Increasing number of cases and outbreaks caused by Candida auris in the EU/EEA, 2020 to 2021. Eurosurveillance, 27(46). doi:https://doi.org/10.2807/1560-7917.es.2022.27.46.2200846.
Randox Attend 2024 Grand National Winning Yard
Randox Laboratories Visits W.P. Mullins’ Yard – Celebrating Success at the 2024 Grand National
Randox Laboratories were thrilled to attend the prestigious 2024 Grand National Winners Yard at W.P. Mullins’ state-of-the-art stables in County Carlow. As the proud sponsors of the Grand National, we had the opportunity to witness first-hand the dedication, precision, and care that go into training champions.
W.P. Mullins, continues to set the standard with his exceptional achievements, including the 2024 winner of the world’s greatest steeplechase I am Maximus.
Randox are grateful to have the opportunity to celebrate the hard work and passion that define winners like W.P. Mullins and his team.
Thank you to everyone at the yard for a warm welcome and an exciting experience!
Check out some of the highlights of our trip below!
Randox Testing Services – Drug and Alcohol Testing
At Randox Testing Services, we provide reliable and cost-effective drug and alcohol testing solutions for a wide range of industries. Sectors we work with include aviation, maritime, manufacturing, and more. Additionally, our Collection Officer Network operates 24 hours a day, 365 days of the year with a target call-out time of 2 hours. With over 40 years of experience in the diagnostics industry, our services not only ensure safety but also compliance in workplaces across the UK and Ireland.
We understand that every industry has unique needs, which is why we craft customised testing packages to meet specific workplace requirements. Whether it’s random testing to deter substance abuse or post-incident testing following an accident, we offer flexible solutions that cater to your business’s safety priorities. Furthermore, our expertise is trusted by industries ranging from safety-critical sectors to the medico-legal field such as family law, ensuring that our clients receive accurate, reliable, and legally defensible results.
- Pre-Employment Testing: Essential for ensuring candidate suitability and maintaining a safe environment for your current workforce.
- Random Testing: A highly effective deterrent for substance abuse, as employees are aware they could be tested at any time, ensuring integrity across all levels of the organisation.
- With-Cause Testing: Conducted when there is suspicion or allegations of drug or alcohol abuse in the workplace, or when drugs and alcohol have been found.
- Post-Incident Testing: Occurs after an accident or incident to determine if drugs or alcohol played a role.
- Abstinence Testing: Used to monitor employees who previously tested positive to ensure they remain abstinent from substance misuse.
We utilise discreet and non-invasive methods for sample collection, offering options such as urine, hair, oral fluid, breath or a combination of these. This enables both short-term and long-term drug profiling. Moreover, our testing methods are designed to suit your organisation’s needs and ensure accuracy and reliability in detecting drug and alcohol use. Each sample is handled following strict chain of custody procedures to guarantee sample integrity from collection to reporting.
We follow a thorough and professional process to deliver tailored drug and alcohol testing solutions:
-
- Consultation: We start with a free consultation to discuss your requirements and create a customised testing package.
- Policy Creation: We help develop a clear and concise workplace drug and alcohol policy that outlines employer rights while protecting employees.
- Policy Implementation: Our training and educational services help you effectively communicate the policy to your team.
- Sample Collection: Our trained officers collect samples at a time and location that suits you, maintaining sample integrity throughout the process.
- Sample Analysis: Using our advanced Biochip Array Technology, we screen samples for a wide range of substances, ensuring reliable and accurate results.
- Results Reporting: Results are delivered confidentially via our secure web portal, with options for alternative methods if preferred.
We test for a wide range of drugs across different panels using both instant testing kits and lab-based confirmatory analysis. This flexibility allows us to meet the diverse needs of our clients, ensuring all substances of concern are covered. Substances include:
| Substances Tested | |||
|---|---|---|---|
| Amphetamine | Phencyclidine | Alcohol | LSD |
| Buprenorphine | Cannabinoids | Barbiturates | Opioids |
| Benzodiazepine | Oxycodone | Benzodiazepine 1 | Mephedrone |
| Cocaine Metabolite | Tramadol | Benzodiazepine 2 | Pregabalin |
| Methadone | EDDP | Methaqualone | Gabapentin |
| Methamphetamine | Ketamine | Fentanyl | Zolpidem |
| Opiates | MDMA/Ecstasy | Propoxyphene | Zopiclone |
- Expertise across various industries, including workplace and medico-legal
- Accurate and reliable testing methods
- Global network of trained sample collection officers
- Customised training and education seminars
- Free policy review and consultation
Randox Testing Services is committed to helping businesses enhance workplace safety, reduce absenteeism, and ensure compliance with drug and alcohol regulations. Contact us today at testingservices@randox.com or call +44 (0) 28 9445 1011 to speak with one of our experts.
Kate Middleton’s diagnosis reminds us that early detection is key
Kate Middleton’s recent cancer diagnosis has highlighted the importance of early detection to us all. Detecting potential health issues early means individuals can work with healthcare professionals to implement treatment plans, lifestyle changes, or preventative measures. These could mitigate, or even prevent the progression of certain diseases.
An article published by the Daily Mail, which focuses on early cancer detection MOT’s, emphasises the importance of preventative testing and treatment throughout. Charlotte Griffiths, who underwent our Everywoman Plus Tumour-Associated Markers test, stated that it is vital to keep a watchful eye for any unexpected bodily changes, such as unexplained bumps or weight loss, which may indicate a presence of cancer.
At Randox Health, we test for a range of different tumour markers, as well as genetic testing, to deliver information on cancer risk to an individual. This aims to empower people to be proactive towards improving their health and makes them aware of any potential future health risks they may have.
It is estimated that 30-50% of all cancer cases are avoidable, and in many cases, early detection is key and can save lives. Cancer that’s diagnosed at an early stage, when it isn’t too large and hasn’t spread, is more likely to be treated successfully.
Spotting cancer at an early stage can save lives, however many people do not have access to the information or services to facilitate this detection. Over 8 million people in the UK are currently awaiting diagnostic testing. At Randox Health, with over 40 years’ experience in working towards improving healthcare worldwide, we have a focus on preventative healthcare; aiming to achieve better health outcomes whilst reducing the burden on clinical services.
At Randox Health we offer genetic risk tests for inherited cancers, including Breast and Ovarian Cancer, Bowel Cancer, and others. In addition, we offer a range of full-body health tests that include common tumour-associated markers.
The results from your tests allow you to get a more accurate representation of your current health status, as well as giving you the ability to make lifestyle changes to potentially prevent future health risks.
Discover our health checks at randoxhealth.com
Randox Collaborate with Transgene in the Field of Bioengineering
Randox are delighted to announce the recent publication of a scientific paper ‘Design and selection of anti-PD-L1 single domain antibody and tumor necrosis factor superfamily ligands for an optimal vectorization in an oncolytic virus.’ The scientific paper showcases the innovative collaboration between Transgene and Randox in the field of bioengineering.
Claire Huguet, PhD (Randox, Head of Biomarker Sciences), introduces the paper.
“Transgene and Randox Laboratories Ltd entered into a scientific collaboration several years ago, with the aim of joining their competences to deliver a novel therapeutic approach to oncology therapies. With Transgene being a world leader in the field of oncolytic viruses and Randox being recognised for its capabilities in targeted antibody discovery, it was a natural synergistic move for Randox to generate a unique, fully blocking PDL-1 sdAb for Transgene to include as a payload in their oncolytic virus vector.
The following research paper, just published in Frontiers in Bioengineering and Biotechnology, summarizes the properties of the vectorized construct, which together with additional payloads, constitutes a promising approach to the development of potent anticancer immunomodulating therapies.”
Wish to read more?
World Diabetes Day
World Diabetes Day!
14th November
Diabetes is a life-long condition that affects millions of people worldwide. It causes blood sugar levels to become abnormally high, which poses a significant danger to your body. Although it’s incurable, it can be monitored and controlled.
Randox Laboratories provide a range of diabetes related diagnostic reagents, that cover many areas from disease recognition and diagnosis to monitoring symptoms and complications associated with the condition.
The three main types of Diabetes are Type 1, Type 2 and Gestational Diabetes.
Type 1 diabetes starts in early childhood, and is caused by a deficiency in the production of insulin by the pancreas. It can be both inherited and acquired. Daily monitoring is required, along with the administration of insulin. Type 1 is when your body can’t naturally produce the hormone insulin, vital for the transportation of glucose in the blood to the cells to energize and fuel our bodies. Your body attacks cells within the pancreas, meaning the body is unable to produce insulin. Without insulin there is no glucose getting into bodily cells, so it builds up in your blood stream causing high blood sugar levels.
Type 2 manifests later in life, it’s when the body produces insulin but does not use it effectively. Can be referred to as insulin resistance. It is more common than Type 1 and usually can be the cause of lack of exercise and excess body fat. However, regardless of weight it can occur in any individual. Type 2 diabetes can be regulated by your diet. Without treatment or action, diabetes can cause many serious problems like damaging the eyes, feet and heart. Some symptoms may include urinating more than usual, feeling lethargic, weight loss, blurred vision and wounds or cuts taking longer to heal.
Gestational diabetes is the development of the condition during pregnancy. It is the result of the body being unable to produce enough insulin to meet the extra needs of the baby and mother. It can cause serious problems if not controlled, to reduce the risks Gestational diabetes is consistently monitored.
Randox Laboratories provide an extensive range of reagents for the accurate testing of diabetes. One of the reagents is Fructosamine in which ‘testing has been identified as being the best for patient care’.
Fructosamine & HbA1c
Fructosamine is a mid-term indicator of diabetic control, as it can provide information on a person’s average blood glucose levels over the previous 14-21 days. Because of it’s shorter time span, it’s often used to evaluate the effectiveness of medication changes and to monitor the treatment of gestational diabetes.
Fructosamine is also particularly useful in situations where HbA1c cannot be reliably measured e.g. haemolytic anaemia, thalassemia or with genetic hemoglobin variants.
HbA1c for example – gives us an indication of what an individual’s average blood sugar level has been over recent weeks/months. This is significant for those who suffer from diabetes because the higher the levels of HbA1c, the higher the chance of an individual suffering from further diabetes related issues.
The latex enhanced immunoturbidimetric method which the RX series utilises makes, the test simple and quick to perform. The removal of the pre-dilution step removes the risk of human error compromising your results. Certified by the National Glycohemoglobin Standardization Program (NGSP), the RX daytona+, RX imola & RX modena are all capable of utilising direct on-board HbA1c which can revolutionise your diabetes testing capabilities.
D-3-Hydroxybutyrate (Ranbut)
D-3-Hydroxybutyrate (Ranbut) is another reagent Randox provides. D-3-Hydroxybutyrate is the most abundant of the three main ketones produced in the body, accounting for 75% of total ketones in the body. Due to the higher levels of D-3-Hydroxybutyrate, it is the more sensitive marker for the diagnosis of ketosis.
Ketosis is a metabolic process, occurring when the body switches from glucose to predominantly fat metabolism for energy production, this happens when carbohydrate availability reaches low levels. The metabolism of fatty acids in the liver, results in the production of chemical by-products known as ketone bodies or ketones. Ketosis occurs when the body produces more ketones than the liver can process.
High levels of ketones present in the body can be dangerous leading to Diabetic Ketoacidosis, which being left untreated can cause damage to vital organs and in some instances may lead to a coma or death.
Benefits of Ranbut include;
• Superior methodology when compared to other commercially available ketone detection tests. For example, the nitroprusside method used in semi-quantitative dipstick tests only detects acetone and acetoacetate. D-3 hydroxybutyrate is the most abundant ketone produced during ketosis the measurement of this analyte is more sensitive and specific.
• Exceptional correlation coefficient of r=0.9954 when compared against other commercially available methods.
• Excellent precision of <3.5% CV.
• Calibrator and controls available offering a complete testing package.
• Applications available detailing instrument-specific settings for the convenient use of the Randox D-3- Hydroxybutyrate (Ranbut) assay on a wide range of clinical chemistry analysers.
• New liquid stable Ranbut assays available.
Non-Esterified Fatty Acids (NEFA)
Non-Esterified Fatty Acids is another reagent Randox provides, which are important metabolites stored in adipose tissue. The dominant source of NEFA is abdominal subcutaneous fat. Cross-sectional studies have consistently documented that circulating NEFA levels are proportional to body fat storage and demonstrated positive correlations between fasting NEFA levels and obesity, insulin resistance and glucose tolerance. It too is an accurate marker regarding diabetes.
Non-Esterified Fatty Acids concentrations are strongly associated with insulin resistance. In the fasting state, the resistance of adipose tissue to the antilipolytic effect of insulin causes the extensive release of NEFA into circulation. Consequently, elevated NEFA levels exacerbate insulin resistance through diminishing insulin- stimulated glucose intake into the skeletal muscle, directly affecting insulin signalling.
Benefits of NEFA include;
• Exceptional correlation coefficient of r=0.98 when compared against other commercially available methods.
• Excellent precision of <5% CV.
• Extensive measuring range of 0.072- 2.24mmol/l for the comfortable detection of clinically important results.
• Calibrator and controls available offering a complete testing package.
• Applications available detailing instrument-specific settings for the convenient use of the Randox NEFA assay on a wide range of clinical chemistry analysers.
Randox’s Reagents available for diagnosis and monitoring of diabetes.
Fructosamine
Glucose
HbA1c
Albumin
Creatinine
Cystatin C
D-3-Hydroxybutyrate
Microalbumin
Non-Esterified Fatty Acids
‘The Randox enzymatic method offers, improved specificity and reliability compared to the conventional NBT-based methods, as the enzymatic method does not suffer from non-specific interferences, unlike the existing methods which can also be time-consuming and difficult to automate. The Randox dedicated Fructosamine calibrator and controls are assigned relative to human serum glycated with 14-C glucose, directly reflecting the nature of the patient sample. Randox provides testing and reagents that are reliable and accurate.’
References
Anon (2023) Types of diabetes, Diabetes UK. Available at: https://www.diabetes.org.uk/diabetes-the-basics/types-of-diabetes (Accessed: 19 September 2023).
NHS (2023) Symptoms of Diabetes, NHS Choices. Available at: https://www.nhs.uk/conditions/type-2-diabetes/symptoms/ (Accessed: 19 September 2023).
Randox (2023) Diabetes Reagents: Biochemistry: Reagents, Randox Laboratories. Available at: https://www.randox.com/diabetes-reagents/ (Accessed: 19 September 2023).
Randox (2023b) Fructosamine: Reagents: Biochemistry, Randox Laboratories. Available at: https://www.randox.com/fructosamine/ (Accessed: 20 September 2023).